Launch of first medical patch to treat early-stage non-melanoma skin cancer (actinic keratosis)1 New report shows 1 in 4 people never check for signs of skin cancer, 1 in 5 rely solely on self-checking, and 1 in 14 (est. 165,000) avoid treatment due to previous bad experiences2 Also reveals GPs are

Link Healthcare is pleased to announce that Amdipharm Mercury Company Limited (AMCo) have decided to invest in their own operations in Australia under the name of Amdipharm Mercury (Australia) Pty Ltd to directly serve the customers in this market. Link Healthcare look forward to focusing on strengthening its position in the ethical specialist pharmaceutical and

Clinigen to acquire Link Healthcare

Tuesday, 22 September 2015 by

On 22 September 2015, Clinigen agreed to acquire Link Healthcare to grow the Group’s presence in the AAA region (Asia, Africa and Australasia) and strengthen its global leadership position in the ethical supply of licensed and unlicensed medicines. To read more | click here

Singapore/Sydney/Auckland/Greifswald: 27 Feb 2015 Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) is pleased to announce signing an exclusive agreement with RIEMSER Pharma GmbH (RIEMSER) of Berlin and Greifswald, Germany for the marketing and distribution of TEPADINA®, thiotepa infusion. Link and RIEMSER will collaborate to obtain marketing authority for the product in both countries.

Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 23/2/15. Specialist pharmaceutical company, LINK Healthcare (‘LINK’) is pleased to announce Australian orphan drug designation for para-amino salicylic acid (PAS) brand PASER®, indicated for use as part of an appropriate combination therapy for the treatment of multi-drug resistant tuberculosis. PASER® is part of Link’s portfolio through a long term relationship with specialist therapeutic

        – The product is a mercaptopurine oral liquid suspension for the treatment of Acute Lymphoblastic Leukaemia – ALLMERCAP™ is a child-friendly formulation offering more flexible, accurate & consistent dosing than the tablet form – LINK has partnered with Nova Laboratories to make the liquid suspension available in Australia   Sydney/Pretoria/Singapore/Hong Kong/Kuala

Avexa Limited – Manufacture of ATC product for Named Patient Scheme completed Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 9th September 2014   Melbourne, Australia, Tuesday 9th September 2014: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that the manufacture of ATC product intended for its Early Access / Named Patient Scheme has been completed successfully, on schedule and is

LINK Healthcare receives marketing approval for DermaScar®  DermaScar® (polysiloxane) is a scar reduction gel for the treatment of keloid and hypertrophic scarring.  Link’s newly formed Pharmacy Division expects more specialist products to follow Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 1st September 2014   Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has

LINK Healthcare receives marketing approval for EQUISIN® in South Africa  EQUISIN®, (exemestane) aromatase inhibitor is used in the treatment of breast cancer  Link’s brand is first-to-market generic to receive approval in South Africa  Link’s range of specialist oncology medicines is set to increase in the coming months Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 26th August 2014

LINK Healthcare receives generic approval for clindamycin hydrochloride 150 mg capsules  Latest addition to LINK’s growing generic range of specialist medicines  For the treatment of serious infections caused by susceptible bacteria Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 12th August 2014   Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has received Australian